Functional outcome measures for NF1-associated optic pathway glioma clinical trials

• Published in: Neurology Vol. 81; no. 21 Suppl 1; p. S15
• Main Authors: Fisher, Michael J, Avery, Robert A, Allen, Jeffrey C, Ardern-Holmes, Simone L, Bilaniuk, Larissa T, Ferner, Rosalie E, Gutmann, David H, Listernick, Robert, Martin, Staci, Ullrich, Nicole J, Liu, Grant T
• Format: Journal Article
• Language: English
• Published: United States 19.11.2013
• Subjects: Child; Clinical Trials as Topic - methods; Clinical Trials as Topic - standards; Consensus; Humans; Neurofibromatosis 1 - complications; Neurofibromatosis 1 - therapy; Optic Nerve Glioma - complications; Optic Nerve Glioma - etiology; Optic Nerve Glioma - therapy; Treatment Outcome; Vision Disorders - diagnosis; Vision Disorders - etiology; Vision Disorders - therapy; Vision Tests - methods; Vision Tests - standards
• ISSN: 1526-632X
• DOI: 10.1212/01.wnl.0000435745.95155.b8

The goal of the Response Evaluation in Neurofibromatosis and Schwannomatosis Visual Outcomes Committee is to define the best functional outcome measures for future neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG) clinical trials. The committee considered the components of vision, other ophthalmologic parameters affected by OPG, potential biomarkers of visual function, and quality of life measures to arrive at consensus-based, evidence-driven recommendations for objective and measurable functional endpoints for OPG trials. Visual acuity (VA) assessments using consistent quantitative testing methods are recommended as the main functional outcome measure for NF1-OPG clinical trials. Teller acuity cards are recommended for use as the primary VA endpoint, and HOTV as a secondary endpoint once subjects are old enough to complete it. The optic disc should be assessed for pallor, as this appears to be a contributory variable that may affect the interpretation of VA change over time. Given the importance of capturing patient-reported outcomes in clinical trials, evaluating visual quality of life using the Children's Visual Function Questionnaire as a secondary endpoint is also proposed. The use of these key functional endpoints will be essential for evaluating the efficacy of future OPG clinical trials.